Asia IPO surge creates alternative capital pathway
Key Questions
What drove Hong Kong's IPO surge in Q1?
HK IPOs raised $14B in Q1, a 5-year high, fueled by 400% AI stock gains and oversubscribed offerings like Diagens ($101M, 1073x). This creates an alternative capital pathway amid US risks. AI momentum is key.
What is the status of India's IPO pipeline?
India saw 38 filings in March, including Manipal, SBI, and Zetwerk, with mega IPOs like Jio and NSE targeting ₹2.5L Cr. This surge bolsters Asia's IPO activity. Monitor upcoming debuts.
Which companies are planning HK IPOs?
Upcoming HK IPOs include ImmunoCure in H2 and Insilico ($293M end-2025, backed by Lilly $2.75B collab). Others like Earendil ($787M), Rebellions ($650M), and MiniMax are in the pipeline. Headwinds from CSRC scrutiny apply.
How is China regulating offshore IPOs?
CSRC is tightening scrutiny on offshore red-chips for tech and biotech, pushing H-shares and slowing pipelines. This is a blow to candidates using offshore vehicles. It favors domestic listings amid Asia surge.
What headwinds face Asia's tech/biotech IPOs?
CSRC's stricter offshore scrutiny slows tech/biotech pipelines despite HK's high. Pushing H-shares amid US risks. Monitor debuts, lockups, and SPACs for opportunities.
HK IPOs $14B Q1 5-yr high (400% AI gains, Diagens $101M 1073x oversub); India 38 filings Mar (Manipal/SBI/Zetwerk) + ₹2.5L Cr (Jio/NSE); ImmunoCure HK H2; Earendil $787M; Insilico HK $293M end-2025 (Lilly $2.75B); Rebellions $650M; MiniMax. Headwinds: CSRC tightening offshore red-chip scrutiny pushing H-shares, slowing tech/biotech pipeline. Monitor debuts/lockups/SPACs amid US risks.